Repaglinide
- Atc Codes:A10BX02
- CAS Codes:135062-02-1
- PHARMGKB ID:135062-02-1
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Edinimel, Enyglid, NovoNorm, Prandin, Repaglinid; Belgium: NovoNorm; Bulgaria: Enyglid, NovoNorm, Prandin, Repaglinide; Cyprus: NovoNorm; Czech Republic: Enyglid, NovoNorm, Prandin, Repaglinid; Denmark: NovoNorm; Estonia: Enyglid, NovoNorm, Prandin, Repaglinid; Finland: NovoNorm; France: NovoNorm; Germany: Apernilid, Edinimel, NovoNorm, Prandin, Repaglinid, Repatifi; Greece: NovoNorm; Hungary: NovoNorm, Prandin; Ireland: Enyglid, NovoNorm, Prandin, Repaglinid; Italy: NovoNorm; Latvia: Enyglid, NovoNorm, Prandin, Repaglinide; Lithuania: Enyglid, NovoNorm, Prandin, Repaglinide; Lithuania: Enyglid, NovoNorm, Prandin, Repaglinide; Luxembourg: Enyglid, NovoNorm, Prandin, Repaglinide; Malta: Enyglid, NovoNorm, Prandin, Repaglinide; Netherlands: Apernilid, Edinimel, Enyglid, NovoNorm, Prandin, Repaglinide; Poland: NovoNorm, Prandin; Portugal: Enyglid, NovoNorm, Prandin, Repaglinida; Romania: Edinimel, NovoNorm, Prandin, Repaglinida, Repaglinide; Slovakia: Enyglid, NovoNorm, Prandin, Repaglinid, Repaglinida, Repaglinide; Slovenia: Enyglid, NovoNorm, Prandin, Repaglinida; Spain: NovoNorm, Prandin; Sweden: Enyglid, NovoNorm, Prandin, Repaglinid, Repaglinide; UK: Prandin.
North America
Canada: GlucoNorm; USA: Prandin.
Latin America
Argentina: Cravenorm, Glukenil, NovoNorm, Sestrine; Brazil: GlucoNorm, NovoNorm, Prandin; Mexico: NovoNorm, Prandin.
Drug combinations
Repaglinide and Metformin
Chemistry
Repaglinide: C~27~H~36~N~2~O~4~. Mw: 452.59. (1)(S)-2-Ethoxy-4-[2-{methyl-1-[2-(1-piperidinyl)phenyl]butylamino}-2-oxoethyl]-benzoic acid; (2)(+)-2-Ethoxy-α-[[(S)-α-isobutyl-o-piperidinobenzyl]carbamoyl]-p-toluic acid. CAS-135062-02-1 (1998).
Pharmacologic Category
Antidiabetic Agents; Meglitinides. (ATC-Code: A10BX02).
Mechanism of action
Nonsulfonylurea hypoglycemic agent of meglitinide class used in management of type 2 diabetes mellitus. Stimulates insulin release from pancreatic β-cells.
Therapeutic use
Management of type 2 diabetes mellitus (non-insulin-dependent) as adjunct to diet and exercise. May be used in combination with metformin or thiazolidinediones.
Pregnancy and lactiation implications
Use of oral agents generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is drug of choice for control of diabetes mellitus during pregnancy. Use not recommended in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to repaglinide or any component of the formulation. Diabetic ketoacidosis, with or without coma. Type 1 diabetes (insulin-dependent).
Warnings and precautions
Repaglinide may cause hypoglycemia. Use with caution in adrenal and/or pituitary impairment (may be more susceptible to glucose-lowering effects). Theoretically, repaglinide may increase cardiovascular events, but there are no long-term studies assessing this concern. Use with caution in moderate-to-severe hepatic impairment, and in severe renal impairment (may be more susceptible to glucose-lowering effects). It may be necessary to discontinue repaglinide and administer insulin if patient exposed to stress (fever, trauma, infection, surgery). Not indicated for use in combination with NPH insulin. Use with caution in malnourished patients (may be more susceptible to glucose-lowering effects).